[{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Piperacillin Sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.

                          Product Name : Piperacillin and Tazobactam for Injection

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 09, 2025

                          Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Zosyn is a combination of piperacillin sodium, which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria and tazobactam sodium having activity against bacteria due to its reduced affinity to penicil...

                          Product Name : Zosyn

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 04, 2023

                          Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Enterobacteriaceae Infections.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 02, 2022

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank